Atopic dermatitis (AD) represents one of the biggest dermatology-related health burdens, associated with significant co-morbidity, including frequent skin infections caused by Staphylococcus aureus.
There are currently no treatments with regulatory approval for such infections, and rampant off-label use of topical and systemic antibiotics has led to significant antibiotic resistance, stewardship problems and reduced wellbeing. Systemic antibiotics also have significant side effects compared to topicals. Accordingly, infected AD is poorly managed.
AntibioTx’s ATx201 is the lead compound from a new class of antibiotics with a novel mode of action, based on a simple chemical scaffold with outstanding properties for the successful topical treatment of infected AD.
By offering a targeted topical treatment that overcomes multidrug resistant pathogens and achieves high concentrations at the site of infection, patients will benefit from a revolutionary new treatment with fewer side-effects, minimum microbiome disruption, and lower risk of hospitalisation.
60 million AD patients are expected in the EU, US and Japan by 2020, each requiring antibiotic treatment more than 1.2 times per year. The remarkable properties of ATx201 in overcoming existing and de novo multidrug resistance responds to the main problems limiting efficient treatment of infected AD and has the potential to make significant impact for patients, physicians and payers. The sustainability of the health care system is promoted by reducing the money spent on less effective treatments, and reducing the number of physician visits and patient hospitalisations.